OpenAlex
PricingAboutJobs
Log inGet started
Work

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

HTML

Year: 2013
Type: review
Source: Annals of the New York Academy of Sciences
DOI: 10.1111/nyas.12122
Authors: David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan, William Berg
Institutions: Novartis (United States), Novartis (Switzerland)
Language: English

Topic: PI3K/AKT/mTOR signaling in cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: everolimus, mTOR inhibitors, renal cell carcinoma, neuroendocrine tumors, breast cancer, tuberous sclerosis complex, anticancer drug development, combination therapy, FDA approval
SDG: Good health and well-being

Open Access status: closed

Funders: Novartis Pharmaceuticals Corporation, U.S. Food and Drug Administration
OpenAlex ID: W1900079465
FWCI: 1.231
Cites: 69
Cited by: 98
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security